REDWOOD CITY, Calif., May 5, 2014 (GLOBE NEWSWIRE) -- Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing a novel, long-acting form of recombinant human growth hormone (rhGH) for the treatment of growth hormone deficiency (GHD), today announced financial results for the first quarter ended March 31, 2014.
Help employers find you! Check out all the jobs and post your resume.
